🔗 Share this article

The Nobel Prize in medical science was granted for transformative discoveries that clarify how the immune system attacks dangerous pathogens while sparing the healthy tissues.

A trio of esteemed scientists—Japan's Shimon Sakaguchi and American scientists Dr. Brunkow and Fred Ramsdell—received this honor.

Their research uncovered specialized "security guards" within the defense system that remove malfunctioning immune cells that could attacking the organism.

The findings are now paving the way for new therapies for immune disorders and malignancies.

These laureates will divide a monetary award valued at 11m Swedish kronor.

Decisive Findings

"Their work has been decisive for comprehending how the body's defenses functions and why we don't all develop serious self-attack conditions," stated the chair of the Nobel Committee.

The trio's research address a core mystery: How does the defense system protect us from countless infections while keeping our healthy cells intact?

Our body's protection system uses immune cells that scan for indicators of infection, even pathogens and germs it has not met before.

Such defenders utilize detectors—called receptors—that are produced randomly in a vast number of combinations.

That gives the defense network the capacity to fight a wide array of threats, but the unpredictability of the mechanism unavoidably produces immune cells that may attack the body.

Security Guards of the Immune System

Researchers previously knew that a portion of these problematic defense cells were eliminated in the thymus—where immune cells develop.

This year's Nobel Prize honors the discovery of T-reg cells—known as the immune system's "security guards"—which travel through the body to neutralize any defenders that assault the healthy cells.

It is known that this process fails in self-attack conditions such as juvenile diabetes, MS, and rheumatoid arthritis.

A Nobel panel stated, "These findings have established a new field of investigation and accelerated the development of new therapies, for instance for cancer and autoimmune diseases."

Regarding cancer, regulatory T-cells block the body from fighting the growth, so studies are focused on reducing their numbers.

In autoimmune diseases, trials are exploring boosting regulatory T-cells so the body is not being harmed. A comparable approach could also be useful in reducing the chances of organ transplant failure.

Pioneering Studies

Prof Sakaguchi, of Osaka University, performed tests on rodents that had their immune gland extracted, leading to self-attack conditions.

He demonstrated that introducing immune cells from other animals could prevent the disease—implying there was a system for blocking defenders from attacking the body.

Dr. Brunkow, from the Institute for Systems Biology in Seattle, and Fred Ramsdell, now at Sonoma Biotherapeutics in a California city, were studying an inherited immune disorder in rodents and people that led to the identification of a genetic factor vital for how regulatory T-cells function.

"Their groundbreaking work has uncovered how the immune system is kept in check by regulatory T cells, preventing it from accidentally targeting the healthy cells," said a prominent biological science specialist.

"This research is a remarkable illustration of how basic physiological study can have far-reaching implications for public health."